Larry Ma1, Theodore M Danoff2, Larry Borish3. 1. Endo Pharmaceuticals Inc, Malvern, Pa. Electronic address: ma.larry@endo.com. 2. Endo Pharmaceuticals Inc, Malvern, Pa. 3. Asthma and Allergic Disease Center, University of Virginia Health System, Charlottesville, Va.
Abstract
BACKGROUND: Anaphylaxis is a serious allergic reaction that can cause death; however, the actual risk of death is unclear. OBJECTIVE: We sought to estimate the case fatality rate among hospitalizations or emergency department (ED) presentations for anaphylaxis and the mortality rate associated with anaphylaxis for the general population. METHODS: This was a population-based epidemiologic study using 3 national databases: the Nationwide Inpatient Sample (NIS; 1999-2009), the Nationwide Emergency Department Sample (NEDS; 2006-2009), and Multiple Cause of Death Data (MCDD; 1999-2009). Sources for these databases are hospital and ED discharge records and death certificates, respectively. RESULTS: Case fatality rates were between 0.25% and 0.33% among hospitalizations or ED presentations with anaphylaxis as the principal diagnosis (NIS+NEDS, 2006-2009). These rates represent 63 to 99 deaths per year in the United States, approximately 77% of which occurred in hospitalized patients. The rate of anaphylaxis-related hospitalizations increased from 21.0 to 25.1 per million population between 1999 and 2009 (annual percentage change, 2.23%; 95% CI, 1.52% to 2.94%), contrasting with a decreasing case fatality rate among hospitalizations (annual percentage change, -2.35%; 95% CI, -4.98% to 0.34%). Overall mortality rates ranged from 0.63 to 0.76 per million population (186-225 deaths per year, MCDD) and appeared stable in the last decade (annual percentage change, -0.31%; 95% CI, -1.54% to 0.93%). CONCLUSION: From 2006 to 2009, the overwhelming majority of hospitalizations or ED presentations for anaphylaxis did not result in death, with an average case fatality rate of 0.3%. Anaphylaxis-related hospitalizations increased steadily in the last decade (1999-2009), but this increase was offset by the decreasing case fatality rate among those hospitalized; both inpatient and overall mortality rates associated with anaphylaxis appeared stable and were well under 1 per million population. Although anaphylactic reactions are potentially life-threatening, the probability of dying is actually very low. With the prevalence of anaphylaxis on the increase, practitioners need to stay vigilant and follow the treatment guidelines to further reduce anaphylaxis-related deaths.
BACKGROUND: Anaphylaxis is a serious allergic reaction that can cause death; however, the actual risk of death is unclear. OBJECTIVE: We sought to estimate the case fatality rate among hospitalizations or emergency department (ED) presentations for anaphylaxis and the mortality rate associated with anaphylaxis for the general population. METHODS: This was a population-based epidemiologic study using 3 national databases: the Nationwide Inpatient Sample (NIS; 1999-2009), the Nationwide Emergency Department Sample (NEDS; 2006-2009), and Multiple Cause of Death Data (MCDD; 1999-2009). Sources for these databases are hospital and ED discharge records and death certificates, respectively. RESULTS: Case fatality rates were between 0.25% and 0.33% among hospitalizations or ED presentations with anaphylaxis as the principal diagnosis (NIS+NEDS, 2006-2009). These rates represent 63 to 99 deaths per year in the United States, approximately 77% of which occurred in hospitalized patients. The rate of anaphylaxis-related hospitalizations increased from 21.0 to 25.1 per million population between 1999 and 2009 (annual percentage change, 2.23%; 95% CI, 1.52% to 2.94%), contrasting with a decreasing case fatality rate among hospitalizations (annual percentage change, -2.35%; 95% CI, -4.98% to 0.34%). Overall mortality rates ranged from 0.63 to 0.76 per million population (186-225 deaths per year, MCDD) and appeared stable in the last decade (annual percentage change, -0.31%; 95% CI, -1.54% to 0.93%). CONCLUSION: From 2006 to 2009, the overwhelming majority of hospitalizations or ED presentations for anaphylaxis did not result in death, with an average case fatality rate of 0.3%. Anaphylaxis-related hospitalizations increased steadily in the last decade (1999-2009), but this increase was offset by the decreasing case fatality rate among those hospitalized; both inpatient and overall mortality rates associated with anaphylaxis appeared stable and were well under 1 per million population. Although anaphylactic reactions are potentially life-threatening, the probability of dying is actually very low. With the prevalence of anaphylaxis on the increase, practitioners need to stay vigilant and follow the treatment guidelines to further reduce anaphylaxis-related deaths.
Authors: Gary Schneider; Sumesh Kachroo; Natalie Jones; Sheila Crean; Philip Rotella; Ruzan Avetisyan; Matthew W Reynolds Journal: Pharmacoepidemiol Drug Saf Date: 2012-01 Impact factor: 2.890
Authors: F Estelle R Simons; Ledit R F Ardusso; M Beatrice Bilò; Vesselin Dimov; Motohiro Ebisawa; Yehia M El-Gamal; Dennis K Ledford; Richard F Lockey; Johannes Ring; Mario Sanchez-Borges; Gian Enrico Senna; Aziz Sheikh; Bernard Y Thong; Margitta Worm Journal: Curr Opin Allergy Clin Immunol Date: 2012-08
Authors: Kari Bohlke; Robert L Davis; Frank DeStefano; S Michael Marcy; M Miles Braun; Robert S Thompson Journal: J Allergy Clin Immunol Date: 2004-03 Impact factor: 10.793
Authors: A Matito; I Alvarez-Twose; J M Morgado; L Sánchez-Muñoz; A Orfao; L Escribano Journal: Curr Allergy Asthma Rep Date: 2014-08 Impact factor: 4.806
Authors: Nicolas Castaño; Seth C Cordts; Kari C Nadeau; Mindy Tsai; Stephen J Galli; Sindy K Y Tang Journal: Biomicrofluidics Date: 2020-04-03 Impact factor: 2.800
Authors: Sarah Patricia Slight; Patrick E Beeler; Diane L Seger; Mary G Amato; Qoua L Her; Michael Swerdloff; Olivia Dalleur; Karen C Nanji; InSook Cho; Nivethietha Maniam; Tewodros Eguale; Julie M Fiskio; Patricia C Dykes; David W Bates Journal: BMJ Qual Saf Date: 2016-03-18 Impact factor: 7.035